Celecoxib in Preventing Non-Small Cell Lung Cancer in Tobacco Smokers

• Status: Completed
• Trial end date: 2009-05-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of cancer. Celecoxib may be effective in preventing lung cancer in tobacco smokers.

PURPOSE: Phase II trial to study the effectiveness of celecoxib in preventing non-small cell lung cancer in tobacco smokers.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jonsson Comprehensive Cancer Center
• Collaborator: National Cancer Institute (NCI)
• Treatments: Celecoxib

Criteria

Inclusion Criteria:

• Age > 45

• Smoked > 20 pack years

Exclusion Criteria:

• Concurrent use of NSAIDs

• Hypersensitivity to celecoxib

• Documented allergic-type reaction to sulfonamides

• History of allergic reaction, urticaria or asthma to aspirin or other NSAIDs

• History of liver dysfunction

• Hypertension or cardiac conditions aggravated by fluid retention and edema

• Previous history of gastrointestinal ulceration, bleeding, or perforation

• Renal dysfunction

• End stage respiratory disease

• Unstable angina

• Other malignancy

• Pregnancy

• Concurrent use of medication known to alter or be affected by alteration of the hepatic p450 2C9 and 2D6 enzymes

• Patents with concurrent medical conditions that may interfere with completion of tests, therapy, or the follow up schedule